Progress toward norovirus vaccines: Considerations for further development and implementation in potential target populations

Expert Review of Vaccines

Volumn 14, Issue 9, 2015, Pages 1241-1253

  Aliabadi, Negar ^a   Lopman, Ben A ^a   Parashar, Umesh D ^a   Hall, Aron J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

calciviridae; epidemiology; gastroenteritis; norovirus; Norwalk agent; vaccine development

Indexed keywords

NOROVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

AGED; ANTIBODY RESPONSE; ARMY; CHILD; FOOD HANDLING; GROUPS BY AGE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION SENSITIVITY; NOROVIRUS INFECTION; NURSING HOME PATIENT; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; REVIEW; SEROLOGY; TRAVEL; VIRUS IMMUNITY; VIRUS TRANSMISSION; CALICIVIRIDAE INFECTIONS; DRUG DEVELOPMENT; GASTROENTERITIS; HEALTH; HEALTH SERVICE; IMMUNOLOGY; ISOLATION AND PURIFICATION; NOROVIRUS; TRENDS; VIROLOGY;

CALICIVIRIDAE INFECTIONS; DRUG DISCOVERY; GASTROENTERITIS; GLOBAL HEALTH; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; NOROVIRUS; VIRAL VACCINES;

EID: 84939471601     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1073110     Document Type: Review

References (119)

1. Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis 2014;14(8): 725-30
2. Patel MM, Widdowson MA, Glass RI, et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008;14(8):1224-31
3. Lanata CF, Fischer-Walker CL, Olascoaga AC, et al. Global causes of diarrheal disease mortality in children < 5 years of age: a systematic review. PLoS One 2013;8(9):e72788
4. Hall AJ, Rosenthal M, Gregoricus N, et al. Incidence of acute gastroenteritis and role of norovirus. Georgia, USA, 2004-2005. Emerg Infect Dis 2011;17(8):1381-8
5. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011;17(1):7-15
6. Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin Infect Dis 2011;52(4): 466-74
7. Hall AJ, Curns AT, McDonald LC, et al. The roles of clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis 2012;55(2):216-23
8. Gastanaduy PA, Hall AJ, Curns AT, et al. Burden of norovirus gastroenteritis in the ambulatory setting-United States, 2001-2009. J Infect Dis 2013;207(7): 1058-65
9. Batz MB, Hoffmann S, Morris JG Jr. Ranking the disease burden of 14 pathogens in food sources in the United States using attribution data from outbreak investigations and expert elicitation. J Food Prot 2012; 75(7):1278-91
10. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013;19(8):1198-205
11. Bresee JS, Marcus R, Venezia RA, et al. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J Infect Dis 2012;205(9):1374-81
12. Bruggink LD, Dunbar NL, Marshall JA. Norovirus genotype diversity in community-based sporadic gastroenteritis incidents: A five-year study. J Med Virol 2015;87(6):961-9
13. Saupe AA, Kaehler D, Cebelinski EA, et al. Norovirus surveillance among callers to foodborne illness complaint hotline, Minnesota, USA, 2011-2013. Emerg Infect Dis 2013;19(8):1293-6
14. Patel MM, Hall AJ, Vinje J, Parashar UD. Noroviruses: a comprehensive review. J Clin Virol 2009;44(1):1-8
15. Hall AJ, Wikswo ME, Pringle K, et al. Vital signs: foodborne norovirus outbreaks - United States, 2009-2012. MMWR Morb Mortal Wkly Rep 2014;63(22):491-5
16. Hall AJ, Wikswo ME, Manikonda K, et al. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis 2013;19(8): 1305-9
17. Richardson C, Bargatze RF, Goodwin R, Mendelman PM. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013; 12(2):155-67
18. Atmar RL, Estes MK. Norovirus vaccine development: next steps. Expert Rev Vaccines 2012;11(9):1023-5
19. Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol 2008;80(8):1468-76
20. Atmar RL, Opekun AR, Gilger MA, et al. Determination of the 50% human infectious dose for norwalk virus. J Infect Dis 2014;209(7):1016-22
21. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009;361(18):1776-85
22. Mattner F, Sohr D, Heim A, et al. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect 2006; 12(1):69-74
23. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. The New England j med 2012;367(22):2126-32
24. Rocha-Pereira J, Neyts J, Jochmans D. Norovirus: targets and tools in antiviral drug discovery. Biochem Pharmacol 2014; 91(1):1-11
25. Hall AJ VJ, Lopman BA, Park GW, et al. Update norovirus outbreak management and disease prevention guidelines. MMWR Morb Mortal Wkly Rep 2011;60(RR03): 1-15
26. Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis 2008; 14(10):1553-7
27. Lopman B, Gastanaduy P, Park GW, et al. Environmental transmission of norovirus gastroenteritis. Curr Opin Virol 2012;2(1): 96-102
28. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in US. children. N Engl J Med 2013;368(12):1121-30
29. Hemming M, Rasanen S, Huhti L, et al. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 2013; 172(6):739-46
30. Phillips G, Tam CC, Conti S, et al. Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol 2010;171(9):1014-22
31. Rockx B, De Wit M, Vennema H, et al. Natural history of human calicivirus infection: a prospective cohort study. Clin Infect Dis 2002;35(3):246-53
32. Saito M, Goel-Apaza S, Espetia S, et al. Multiple norovirus infections in a birth cohort in a Peruvian periurban community. Clin Infect Dis 2014;58(4):483-91
33. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 2013;19(8):1260-7
34. Hickman D, Jones MK, Zhu S, et al. The effect of malnutrition on norovirus infection. mBio 2014;5(2):e01032-13
35. Trivedi TK, Desai R, Hall AJ, et al. Clinical characteristics of norovirus-associated deaths: a systematic literature review. Am J Infect Control 2013; 41(7):654-7
36. Verhoef L, Koopmans M, Vanp W, et al. The estimated disease burden of norovirus in The Netherlands. Epidemiol Infect 2013; 141(3):496-506
37. Harris JP, Edmunds WJ, Pebody R, et al. Deaths from norovirus among the elderly, England and Wales. Emerg Infect Dis 2008; 14(10):1546-52
38. Kambhampati A, Koopmans M, Lopman BA. Burden of norovirus in healthcare facilities and strategies for outbreak control. J Hosp Infect 2015;89(4): 296-301
39. Desai R, Hembree CD, Handel A, et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin Infect Dis 2012;55(2):189-93
40. Trivedi TK, DeSalvo T, Lee L, et al. Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009-2010. Jama 2012;308(16):1668-75
41. Ajami NJ, Kavanagh OV, Ramani S, et al. Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med 2014; 21(1):6-11
42. Ajami N, Koo H, Darkoh C, et al. Characterization of norovirus-associated traveler's diarrhea. Clin Infect Dis 2010; 51(2):123-30
43. Koo HL, Ajami NJ, Jiang ZD, et al. Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol 2010;48(5):1673-6
44. Zlot A, Simckes M, Vines J, et al. Norovirus outbreak associated with a natural lake used for recreation - Oregon, 2014. MMWR Morb Mortal Wkly Rep 2015; 64(18):485-90
45. Wikswo ME, Hall AJ, Centers for Disease C. Prevention. Outbreaks of acute gastroenteritis transmitted by person-to-person contact-United States, 2009-2010. MMWR Surveill Summ 2012;61(9):1-12
46. Matthews JE, Dickey BW, Miller RD, et al. The epidemiology of published norovirus outbreaks: a review of risk factors associated with attack rate and genogroup. Epidemiol Infect 2012;140(7):1161-72
47. Verhoef L, Depoortere E, Boxman I, et al. Emergence of new norovirus variants on spring cruise ships and prediction of winter epidemics. Emerg Infect Dis 2008;14(2): 238-43
48. Kirking HL, Cortes J, Burrer S, et al. Likely transmission of norovirus on an airplane, October 2008. Clinical infectious diseases : an official publication of the Infectious. Clin Infect Dis 2010;50(9):1216-21
49. Riddle MS, Sanders JW, Putnam SD, Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. Am J Trop Med Hyg 2006;74(5):891-900
50. Thornton SA, Sherman SS, Farkas T, et al. Gastroenteritis in US Marines during operation Iraqi freedom. Clin Infect Dis 2005;40(4):519-25
51. Aronson NE, Sanders JW, Moran KA. In harm's way: infections in deployed American military forces. Clin Infect Dis 2006;43(8):1045-51
52. Ye X, Van JN, Munoz FM, et al. Noroviruses as a cause of diarrhea in immunocompromised pediatric hematopoietic stem cell and solid organ transplant recipients. Am J Transplant 2015;15(7):1874-81
53. Woodward JM, Gkrania-Klotsas E, Cordero-Ng AY, et al. The role of chronic norovirus infection in the enteropathy associated with common variable immunodeficiency. Am J Gastroenterol 2015;110(2):320-7
54. Hoffmann D, Hutzenthaler M, Seebach J, et al. Norovirus GII.4 and GII.7 capsid sequences undergo positive selection in chronically infected patients. Infect Genet Evol 2012;12(2):461-6
55. Vega E, Donaldson E, Huynh J, et al. RNA populations in immunocompromised patients as reservoirs for novel norovirus variants. J Virol 2014;88(24):14184-96
56. Munir N, Liu P, Gastanaduy P, et al. Norovirus infection in immunocompromised children and children with hospital-acquired acute gastroenteritis. J Med Virol 2014;86(7):1203-9
57. Hall AJ, Eisenbart VG, Etingue AL, et al. Epidemiology of foodborne norovirus outbreaks, United States, 2001-2008. Emerg Infect Dis 2012;18(10):1566-73
58. Fankhauser RL, Monroe SS, Noel JS, et al. Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States. J Infect Dis 2002;186(1):1-7
59. Meakins SM, Adak GK, Lopman BA, O'Brien SJ. General outbreaks of infectious intestinal disease (IID) in hospitals, England and Wales, 1992-2000. J Hosp Infect 2003; 53(1):1-5
60. Bruggink LD, Oluwatoyin O, Sameer R, et al. Molecular and epidemiological features of gastroenteritis outbreaks involving genogroup I norovirus in Victoria, Australia, 2002-2010. J Med Virol 2012; 84(9):1437-48
61. Kroneman A, Verhoef L, Harris J, et al. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. J Clin Microbiol 2008;46(9):2959-65
62. Sukhrie FH, Teunis P, Vennema H, et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis 2012;54(7):931-7
63. Kapikian AZ, Wyatt RG, Dolin R, et al. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol 1972;10(5):1075-81
64. Vinje J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol 2015;53(2):373-81
65. Kroneman A, Vega E, Vennema H, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013;158(10):2059-68
66. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992;66(11):6527-32
67. Jones MK, Watanabe M, Zhu S, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 2014; 346(6210):755-9
68. Hoa Tran TN, Trainor E, Nakagomi T, et al. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants. J Clin Virol 2013;56(3):185-93
69. Vega E, Barclay L, Gregoricus N. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol 2014;52(1): 147-55
70. Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis 2009;200(5):802-12
71. Debbink K, Lindesmith LC, Donaldson EF, et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis 2013;208(11):1877-87
72. van Beek J, Ambert-Balay K, Botteldoorn N, et al. Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012. Euro Surveill 2013;18(1):8-9
73. Sakon N, Yamazaki K, Nakata K, et al. Impact of genotype-specific herd immunity on the circulatory dynamism of norovirus: a 10-year longitudinal study of viral acute gastroenteritis. J Infect Dis 2015;211(6): 879-88
74. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev 2008;225:190-211
75. Lindesmith LC, Donaldson EF, Baric RS. Norovirus GII.4 strain antigenic variation. J Virol 2011;85(1):231-42
76. Cannon JL, Lindesmith LC, Donaldson EF, et al. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J virol 2009;83(11):5363-74
77. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012;8(5):e1002705
78. Huhti L, Blazevic V, Puustinen L, et al. Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013. Infect Genet Evol 2014;26:65-71
79. Leshem E, Barclay L, Wikswo M, et al. Genotype GI.6 norovirus, United States, 2010-2012. Emerg Infect Dis 2013;19(8): 1317-20
80. Ahmed SF, Klena JD, Mostafa M, et al. Viral gastroenteritis associated with genogroup II norovirus among US. military personnel in Turkey, 2009. PloS One 2012; 7(5):e35791
81. Fu J, Ai J, Jin M, et al. Emergence of a new GII.17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015. Euro Surveill 2015;20:24
82. Lu J, Sun L, Fang L, et al. Gastroenteritis Outbreaks Caused by Norovirus GII.17, Guangdong Province, China, 2014-2015. Emerg Infect Dis 2015;21(7):1240-2
83. Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat med 2003; 9(5):548-53
84. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012;206(9):1386-93
85. Yazawa S, Yokobori T, Ueta G, et al. Blood group substances as potential therapeutic agents for the prevention and treatment of infection with noroviruses proving novel binding patterns in human tissues. PLoS ONE 2004;9(2):e89071
86. Thorven M, Grahn A, Hedlund KO, et al. A homozygous nonsense mutation (428G-> A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J virol 2005; 79(24):15351-5
87. Currier RL, Payne DC, Staat MA, et al. Innate susceptibility to norovirus infections influenced by FUT2 genotype in a united states pediatric population. Clin Infect Dis 2015;60(11):1631-8
88. Lopman BA, Trivedi T, Vicuna Y, et al. Norovirus infection and disease in an Ecuadorian birth cohort: Association of certain norovirus genotypes with host FUT2 secretor status. J Infect Dis 2015; 211(11):1813-21
89. Murakami K, Kurihara C, Oka T, et al. Norovirus binding to intestinal epithelial cells is independent of histo-blood group antigens. PLoS One 2013;8(6):e66534
90. Ryder RW, Singh N, Reeves WC, et al. Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands. J Infect Dis 1985;151(1):99-105
91. Nurminen K, Blazevic V, Huhti L, et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011;83(3): 525-31
92. Lew JF, Valdesuso J, Vesikari T, et al. Detection of norwalk virus or norwalk-like virus infections in finnish infants and young children. J Infect Dis 1994;169(6):1364-7
93. Malm M, Uusi-Kerttula H, Vesikari T, Blazevic V. High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children. J Infect Dis 2014;210(11):1755-62
94. Parker SP, Cubitt WD, Jiang XJ, Estes MK. Seroprevalence studies using a recombinant Norwalk virus protein enzyme immunoassay. J Med Virol 1994;42(2): 146-50
95. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 1990;161(1): 18-21
96. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010;202(8):1212-18
97. Wyatt RG, Dolin R, Blacklow NR, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 1974;129(6):709-14
98. Treanor JJ, Jiang X, Madore HP, Estes MK. Subclass-specific serum antibody responses to recombinant Norwalk virus capsid antigen (rNV) in adults infected with Norwalk, Snow Mountain, or Hawaii virus. J Clin Microbiol 1993;31(6):1630-4
99. Noel JS, Ando T, Leite JP, et al. Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. J Med Virol 1997;53(4):372-83
100. Ramani S, Neill FH, Opekun AR, et al. Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis 2015;212(3): 397-405
101. Parrino TA, Schreiber DS, Trier JS, et al. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 1977;297(2):86-9
102. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010;202(11): 1649-58
103. Tacket CO, Sztein MB, Losonsky GA, et al. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clinical Immunology 2003; 108(3):241-7
104. Zhu S, Regev D, Watanabe M, et al. Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains. PLoS pathog 2013;9(9):e1003592
105. LoBue AD, Lindesmith L, Yount B, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006; 24(24):5220-34
106. Tamminen K, Lappalainen S, et al. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PloS One 2013;8(7):e70409
107. Sundararajan A, Sangster MY, Frey S, et al. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine 2015;33(4):568-76
108. Lindesmith LC, Ferris MT, Mullan CW, et al. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS med 2015;12(3): e1001807
109. Czako R AR, Opekun AR, Gilger MA, et al. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clinical and Vaccine Immunology 2015;22(2):221-8
110. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011;365(23):2178-87
111. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22(3):259-67
112. Bok K, Parra GI, Mitra T, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci USA 2011;108(1):325-30
113. Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus vaccine against experimental human GII.4 Virus illness: A challenge study in healthy adults. J Infect Dis 2014; 211(6):870-8
114. Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011;30(1 Suppl):S1-5
115. Bartsch SM, Lopman BA, Hall AJ, et al. The potential economic value of a human norovirus vaccine for the United States. Vaccine 2012;30(49):7097-104
116. Mirelman AJ, Ballard SB, Saito M, et al. effectiveness of norovirus vaccination in children in Peru. Vaccine 2015;33(27): 3084-91
117. (ACIP) ACoIP. General Recommendations on Immunization. MMWR Morb Mortal Wkly Rep 2011;60:2
118. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009;27(6):882-7
119. O'Reilly FW, Cran GW, Stevens AB. Factors affecting influenza vaccine uptake among health care workers. Occup Med (Chic Ill) 2005;55(6):474-9